Shares of Quantum BioPharma (QNTM) surged 15% in pre-market trading on Monday after the biotech firm signed a binding agreement with Allucent to support a planned Phase 2 trial of its Lucid-MS therapy for multiple sclerosis.
The study will evaluate the drug’s safety, effectiveness, and tolerability, with initiation expected in the second quarter of 2026, Quantum BioPharma said.
Lucid-MS is designed to protect nerves by targeting Demyelination, a key factor for multiple sclerosis progression. Allucent will provide end-to-end support for the clinical trial, including execution and data management.
“This innovative mechanism represents a differentiated therapeutic approach in the global MS market where an estimated 2.8 million people suffer and where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration,” said Andrzej Chruscinski, VP, Scientific and Clinical Affairs at Quantum BioPharma.
Get updates to this developing story on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.